Octave Bioscience Announces Strategic Investment from the Merck Global Health Innovation Fund to Transform Disease Measurement and Care for Patients with Neurodegenerative Diseases

MENLO PARK, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund (Merck GHIF) has made a strategic investment in Octave to further advance its industry-leading capabilities in...

Click to view original post